Carol Kreider, APRN
Family · West Palm Beach, FLNPI 1063924769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,592, more than ten times the $80 reported in 2021. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $26.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$442
- Amgen$355
- Novo Nordisk$312
- Sequel Med Tech, LLC$267
- Sanofi-aventis U.S. LLC$232
- Medtronic$230
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,70499%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 6 | $442 |
| Amgen | 20 | $355 |
| Novo Nordisk | 18 | $312 |
| Sequel Med Tech, LLC | 7 | $267 |
| Sanofi-aventis U.S. LLC | 8 | $232 |
| Medtronic | 2 | $230 |
| Lilly USA, LLC | 6 | $199 |
| AbbVie | 9 | $181 |
| Bayer | 8 | $174 |
| GSK | 4 | $151 |
| Insulet Corporation | 7 | $145 |
| Mannkind Corporation | 6 | $133 |
| Neurocrine Biosciences, Inc. | 1 | $118 |
| Corcept Therapeutics | 5 | $101 |
| Madrigal Pharmaceuticals | 3 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Globus Medical | 3 | $71 |
| Organon | 2 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Antares Pharma, Inc. | 2 | $44 |
| Radius Health, Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $39 |
| Vivus LLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Alvogen Inc | 1 | $18 |
| Abbott | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Cequr Corporation | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$397
- DEXCOM STELO GLUCOSE BIOSENSOR$296
- TWIIST$138
- MINIMED 780G$138
- ZEPBOUND$125
- Ozempic$122
- CRENESSITY$118
- EVENITY$113
How this compares
$3,755 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $61,503 |
| OzempicSemaglutide | 45 | $55,936 |
| MounjaroTirzepatide | 36 | $40,446 |
| TrulicityDulaglutide | 16 | $20,459 |
| RybelsusSemaglutide | 11 | $17,055 |
| JanuviaSitagliptin Phosphate | 17 | $15,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $14,811 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $12,432 |
| Novolog FlexpenInsulin Aspart | 22 | $6,100 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $4,237 |
| SynthroidLevothyroxine Sodium | 23 | $1,986 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $1,851 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $595 |
| Atorvastatin Calcium | 80 | $584 |
| Levothyroxine Sodium | 56 | $407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $312 | $72,99056 claims |
| Boehringer IngelheimJardiance | $39 | $61,50358 claims |
| Lilly USA, LLCMounjaro, Trulicity | $199 | $60,90552 claims |
| GSKTrelegy Ellipta | $151 | $14,81121 claims |
| AbbVieSynthroid | $181 | $1,98623 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $40756 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in West Palm Beach
- Katharine TamburroWest Palm Beach$67K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.